Skip to main content
SpringerLink
Log in

2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients

  • Review
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with various malignancies ranging from early to end stages. In light of frequent changes to the guidelines for optimal management of CINV, we undertook this narrative review to compare the most recent guidelines published by ASCO (2020), NCCN (2023), MASCC/ESMO (2023), and CCO (2019). The processes undertaken by each organization to evaluate existing literature were also described. Although ASCO, NCCN, MASCC/ESMO, and CCO guidelines for the treatment and prevention of CINV share many fundamental similarities, the literature surrounding low and minimal emetic risk regimens is lacking. Current data regarding adherence to these guidelines is poor and warrants further investigation to improve care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

All data used in this paper can be found in the reference section.

References

  1. Coates A, Abraham S, Kaye SB et al (1983) On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208

    Article  CAS  PubMed  Google Scholar 

  2. Vardy JL, Liew A, Warby A et al (2022) On the receiving end: have patient perceptions of the side-effects of cancer chemotherapy changed since the twentieth century? Support Care Cancer 30:3503–3512

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kuchuk I, Bouganim N, Beusterien K et al (2013) Patient perceptions about potential side effects and benefits from chemotherapy agents. J Clin Oncol 31:6595–6595

    Article  Google Scholar 

  4. Matzka M, Köck-Hódi S, Jahn P et al (2018) Relationship among symptom clusters, quality of life, and treatment-specific optimism in patients with cancer. Support Care Cancer 26:2685–2693

    Article  PubMed  PubMed Central  Google Scholar 

  5. Grunberg SM, Warr D, Gralla RJ et al (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art. Support Care Cancer 19:S43–S47

    Article  PubMed  Google Scholar 

  6. Navari RM (2015) Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int 2015:595894–595896

    Article  PubMed  PubMed Central  Google Scholar 

  7. Navari RM, Ruddy KJ, Leblanc TW et al (2019) Impact of addition of carboplatin AUC <= 4 to antiemetic guidelines for triple antiemetic prophylaxis: a gap in quality of care, guideline adoption, and avoiding acute care. Proc Am Soc Clin Oncol 16:e132–e138

    Google Scholar 

  8. Gao J, Zhao J, Jiang C et al (2022) Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study. Support Care Cancer 30:6225–6232

    Article  PubMed  PubMed Central  Google Scholar 

  9. Razvi Y, Chan S, McFarlane T et al (2019) ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27:87–95

    Article  PubMed  Google Scholar 

  10. Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782–2797

    Article  CAS  PubMed  Google Scholar 

  11. Hesketh PJ, Kris MG, Basch E et al (2017) JOURNAL OF CLINICAL ONCOLOGY Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240–3261

    Article  CAS  PubMed  Google Scholar 

  12. Berger MJ, Agarwal R, Anand S et al (2023) NCCN guidelines version 1.2023 antiemesis continue, https://www.nccn .

  13. Summary of 2019 antiemetic recommendations. 2019

  14. Dupuis LL, Sung L, Molassiotis A et al (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children. Support Care Cancer 25:323–331

    Article  PubMed  Google Scholar 

  15. Molassiotis A, Lou AM, Fleury M et al (2023) MASCC/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies. Support Care Cancer 2023(32):30

    Google Scholar 

  16. Olver I, Clark-Snow R, Ruhlmann CH et al (2024) 2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Support Care Cancer 32:37

    Article  Google Scholar 

  17. Rapoport BL, Herrstedt J, Snow RC et al (2024) 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 32:36

    Article  Google Scholar 

  18. Scotté F, Schwartzberg L, Lihara H et al (2024) 2023 updated MASCC/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Supportive Care in Cancer 32:45

    Article  Google Scholar 

  19. Herrstedt J, Celio L, Hesketh P, et al (2024) 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Supportive Care in Cancer 32. https://doi.org/10.1007/s00520-023-08221-4

  20. Jordan K, Gralla R, Rizzi G et al (2016) Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Support Care Cancer 24:4617–4625

    Article  PubMed  Google Scholar 

  21. Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242–249

    Article  CAS  PubMed  Google Scholar 

  22. Vimolchalao V, Sakdejayont S, Wongchanapai P et al (2020) The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Int J Clin Oncol 25:396–402

    Article  PubMed  Google Scholar 

  23. Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134–142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bajpai J, Kapu V, Rath S et al (2024) Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol.  https://doi.org/10.1016/S1470-2045(23)00628-9

  25. Zhao Y, Yang Y, Gao F et al (2022) A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). EClinicalMedicine 55. https://doi.org/10.1016/j.eclinm.2022.101771

  26. Jeon SY, Han HS, Bae WK et al (2019) A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: results of the Korean South West Oncology Group (KSWOG) study. Cancer Res Treat 51:90–97

    Article  CAS  PubMed  Google Scholar 

  27. Ng TL, Hutton B, Clemons M (2015) Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist 20:576–583

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Hernandez Torres C, Mazzarello S, Ng T et al (2015) Defining optimal control of chemotherapy-induced nausea and vomiting—based on patients’ experience. Support Care Cancer 23:3341–3359

    Article  PubMed  Google Scholar 

  29. Ng T, Mazzarello S, Wang Z et al (2016) Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. Breast Cancer Res Treat 155:337–344

    Article  CAS  PubMed  Google Scholar 

  30. Hutton B, Clemons M, Mazzarello S et al (2015) Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer—an inspection of the evidence base informing clinical decision-making. Cancer Treat Rev 41:951–959

    Article  CAS  PubMed  Google Scholar 

  31. Yamamoto S, Iihara H, Uozumi R et al (2021) Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials. BMC Cancer 21:832

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Radhakrishnan V, Joshi A, Ramamoorthy J et al (2019) Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: a double-blind, placebo-controlled, phase III randomized trial. Pediatr Blood Cancer 66:e27551

    Article  PubMed  Google Scholar 

  33. Food and Drug Administration  (2019) Highlights of prescribing information: EMEND (fosaprepitant) for injection, for intravenous use, www.fda.gov/medwatch

  34. Aapro M, Scotté F, Escobar Y et al (2021) Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist 26:e1073–e1082

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. Journal of Supportive Oncology 9:188–195

    Article  CAS  PubMed  Google Scholar 

  36. McKinnon K, Jupp J, Ghosh S et al (2019) Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals. Pediatr Blood Cancer 66:e27488

    Article  PubMed  Google Scholar 

  37. Kacar M, MacDonald P, Gibson P (2023) Addressing adherence to guidelines on prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients. Pediatr Blood Cancer 70:e30210

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

    Samantha K. F. Kennedy, Carlo DeAngelis, Flay Charbonneau, Katie Wang, Mark Pasetka, Adrian Wai Chan, Thenugaa Rajeswaran, Milena Gojsevic, Edward Chow & Katarzyna J. Jerzak

  2. Department of Internal Medicine, Santa Barbara Cottage Hospital, Santa Barbara, CA, USA

    Shannon Goodall

  3. Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore

    Shing Fung Lee

  4. Department of Clinical Oncology, Tuen Mun Hospital, New Territories West Cluster, Hospital Authority, Tuen Mun, Hong Kong

    Shing Fung Lee

  5. Scarborough Health Network, Oncology Pharmacy, Toronto, ON, Canada

    Allison Jocko

  6. Oncology and Endoscopy, St Michael Hospital, Toronto, ON, Canada

    Yoo-Joung Ko

  7. Department of Oncology, Princess Margaret Hospital, Kowloon, Hong Kong

    Henry C. Y. Wong

  8. Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, USA

    Richard J. Gralla

  9. Division of Medical Oncology, Ottawa Hospital Research Institute, Department of Medicine, University of Ottawa, Ottawa, ON, Canada

    Terry L. Ng

Authors
  1. Samantha K. F. Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shannon Goodall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shing Fung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlo DeAngelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Allison Jocko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Flay Charbonneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Katie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mark Pasetka
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoo-Joung Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Henry C. Y. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Adrian Wai Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Thenugaa Rajeswaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Milena Gojsevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Edward Chow
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Richard J. Gralla
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Terry L. Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Katarzyna J. Jerzak
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SKFK, SFL, and SG conducted data extraction. SKFK wrote the body of the manuscript. HCYW and AWC checked the data extraction for accuracy. SKFK, SFL, and SG incorporated the comments from other authors. Drs. SFL, TLN, and KJJ contributed equally as senior authors overseeing the project. SKFK, SG, SFL, CD, AJ, PC, KW, MP, YJK, HCYW, AWC, TR, MG, EC, RJG, TLN, and KJJ all provided significant edits to the manuscript and gave a final approval of the manuscript.

Corresponding author

Correspondence to Samantha K. F. Kennedy.

Ethics declarations

Ethical approval

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Drs. Shing Fung Lee, Terry L. Ng, and Katarzyna J. Jerzak contributed equally as senior authors.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kennedy, S.K.F., Goodall, S., Lee, S.F. et al. 2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer 32, 280 (2024). https://doi.org/10.1007/s00520-024-08462-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00520-024-08462-x

Keywords

Search

Navigation